An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part II: In Vitro Transcribed mRNA Vector Design for Inoculation Against Infectious Agent Variants

Glaucia C Pereira

doi:10.1007/978-1-0716-2716-7_17

An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part II: In Vitro Transcribed mRNA Vector Design for Inoculation Against Infectious Agent Variants

Methods Mol Biol. 2023:2575:323-340. doi: 10.1007/978-1-0716-2716-7_17.

Author

Glaucia C Pereira¹

Affiliation

¹ Bioengineering Department, Imperial College London, London, UK. glaucia.daconceicaopereira12@alumni.imperial.ac.uk.

PMID: 36301484
DOI: 10.1007/978-1-0716-2716-7_17

Abstract

A fully automated strategy to handle antigenic variability in immunisation protocols is here presented. The method comprises of (1) nanopore sequencing of infectious agent variants, with focus on the SARS-CoV-2 and its variants, followed by (2) in-vitro transcribed mRNA vector design for immunotherapy. This chapter introduces the mRNA vector design protocol and Chapter 16 presents the nano-pore sequencing step.

Keywords: ACE2; Adaptive immune system; Antigenic variability; B cell; Coronaviruses; Immunisation metrics for varied infectious agents; Innate immune system; Nucleic acids therapeutics; S1/S2 inserts; SARS-CoV-2; Spike protein; T cell; TMPRSS2; mRNA vector design.

MeSH terms

Antigenic Variation
COVID-19* / prevention & control
Humans
Immunization
RNA, Messenger / genetics
SARS-CoV-2 / genetics
Spike Glycoprotein, Coronavirus* / genetics

Substances

Spike Glycoprotein, Coronavirus
RNA, Messenger
spike protein, SARS-CoV-2